Zhengye Biotechnology Holding Limited (ZYBT) Revenue History
Annual and quarterly revenue from 2021 to present
ZYBT Revenue Over Time (2021–2024)
ZYBT Revenue Growth History
1 of 3 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- +21.6%
- FY2023 revenue growth
- -18.7%
- FY2024 revenue growth
- -12.0%
ZYBT Revenue Analysis (2021–2024)
Current Revenue & Growth
As of June 28, 2026, Zhengye Biotechnology Holding Limited (ZYBT) generated trailing twelve-month (TTM) revenue of $0.
Historical Growth Trajectory
ZYBT's historical revenue data shows a 3-year CAGR of -4.5%. Zhengye Biotechnology Holding Limited's highest annual revenue of $260.3 million was recorded in 2022.
Peer Comparison
Compared to Healthcare sector peers — including ATXG (-18.5% YoY), CLPS (+1.6% YoY), and TAOP (-15.1% YoY). Compare ZYBT vs ATXG →
ZYBT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ZYBTCurrent | $0 | - | - | 8.8% | |
 ATXG | $4M | -18.5% | -16.3% | -43.5% | |
 CLPS | $164M | +1.6% | +13.0% | -4.0% | |
 TAOP | $31M | -15.1% | +22.7% | -29.0% | |
 CNET | $5M | -75.3% | -34.5% | -42.3% |
ZYBT Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $186.4M | -12.0% | $91.3M | 49.0% | $16.4M | 8.8% |
| 2023 | $211.7M | -18.7% | $129.9M | 61.4% | $45.0M | 21.3% |
| 2022 | $260.3M | +21.6% | $153.5M | 59.0% | $65.8M | 25.3% |
| 2021 | $214.1M | - | $125.4M | 58.6% | $52.4M | 24.5% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZYBT — Frequently Asked Questions
Quick answers to the most common questions about buying ZYBT stock.
Is ZYBT's revenue growth accelerating or slowing?
ZYBT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ZYBT's revenue history from 2021 to 2026?
Zhengye Biotechnology Holding Limited (ZYBT) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ZYBT's long-term revenue growth rate (CAGR)?
Zhengye Biotechnology Holding Limited's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ZYBT.
Why does ZYBT's quarterly revenue fluctuate?
ZYBT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Zhengye Biotechnology Holding Limited's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is ZYBT's revenue distributed by segment?
ZYBT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ZYBT's revenue compare to industry peers?
Zhengye Biotechnology Holding Limited (ZYBT) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.